Literature DB >> 19820005

Familial and phenotypic associations of the aldosterone Renin ratio.

Samantha Alvarez-Madrazo1, Sandosh Padmanabhan, Bongani M Mayosi, Hugh Watkins, Peter Avery, A Michael Wallace, Robert Fraser, Eleanor Davies, Bernard Keavney, John M Connell.   

Abstract

CONTEXT: The aldosterone to renin ratio (ARR) is a marker of aldosterone excess, widely used to screen for primary aldosteronism (PA). The significance of a raised ARR in normotensive and hypertensive subjects and the phenotypic and familial factors affecting it are unclear.
OBJECTIVE: We estimated the distribution and heritability of the ARR and tested for associations between ARR and blood pressure (BP) with 11 polymorphisms at the CYP11B1/CYP11B2 locus. DESIGN AND
SETTING: A total of 1172 individuals from 248 Caucasian families ascertained via a hypertensive proband were evaluated. MAIN OUTCOME MEASURE: Plasma aldosterone was measured by RIA, and plasma renin concentration was measured by the LIAISON Direct Renin chemiluminescent immunoassay.
RESULTS: Unadjusted and adjusted ARR were continuously distributed in normotensives and hypertensives, with no evidence of a cutoff that would identify a separate population with PA. Median ARR was 4.19 ng/liter per mIU/liter (range, 0.04-253.16). ARR levels were higher in females and associated with age, body mass index, and potassium. Antihypertensive agents had significant predictable effects on the ARR. Renin was negatively associated, and ARR was positively associated with ambulatory BP readings (P < 0.001) in subjects not taking antihypertensives. The heritability of the ARR was 38.1% (P < 10(-8)). Plasma aldosterone, but not ARR, was influenced by the intron 2 conversion variation in the CYP11B2 gene (beta = -0.07; P = 0.04).
CONCLUSIONS: The ARR is continuously distributed, is influenced by genetic and environmental factors, and is not a marker of a distinct pathological abnormality but possibly reflects the long-term influence of aldosterone on cardiovascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820005     DOI: 10.1210/jc.2009-1406

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  The role of aldosteronism in causing obesity-related cardiovascular risk.

Authors:  David A Calhoun; Kumar Sharma
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

2.  Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay.

Authors:  Ryo Morimoto; Yoshikiyo Ono; Yuta Tezuka; Masataka Kudo; Sachiko Yamamoto; Toshiaki Arai; Celso E Gomez-Sanchez; Hironobu Sasano; Sadayoshi Ito; Fumitoshi Satoh
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

3.  Dysregulated aldosterone secretion in persons of African descent with endothelin-1 gene variants.

Authors:  Jia W Tan; Tina Gupta; Worapaka Manosroi; Tham M Yao; Paul N Hopkins; Jonathan S Williams; Gail K Adler; Jose R Romero; Gordon H Williams
Journal:  JCI Insight       Date:  2017-12-07

4.  A marked proportional rise in IVC aldosterone following cosyntropin administration during AVS is a signal to the presence of adrenal hyperplasia in primary aldosteronism.

Authors:  G A Kline; J L Pasieka; A Harvey; B So; V C Dias
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

5.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

6.  Unadjusted Plasma Renin Activity as a "First-Look" Test to Decide Upon Further Investigations for Primary Aldosteronism.

Authors:  Peter Rye; Alex Chin; Janice Pasieka; Benny So; Adrian Harvey; Gregory Kline
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-03-10       Impact factor: 3.738

7.  Mild Adrenal Steroidogenic Defects and ACTH-Dependent Aldosterone Secretion in High Blood Pressure: Preliminary Evidence.

Authors:  João Martin Martins; Sónia do Vale; Ana Filipa Martins
Journal:  Int J Endocrinol       Date:  2014-12-15       Impact factor: 3.257

8.  Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study.

Authors:  Kennosuke Ohashi; Takeshi Hayashi; Yui Watanabe; Koichiro Hara; Rikako Ukichi; Hiroshi Asano; Hirofumi Suzuki; Kenji Yamashiro; Katsuyoshi Tojo; Masaya Sakamoto; Kazunori Utsunomiya
Journal:  J Clin Med Res       Date:  2017-12-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.